deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT02091245

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.

Sponsor: Dana-Farber Cancer Institute

Conditions Chronic Myelogenous Leukemia (CML) in Blast Crisis Refractory Acute Lymphoblastic Leukemia (ALL) Refractory Acute Myelogenous Leukemia (AML) Refractory Biphenotypic Leukemia Refractory Mixed Lineage Leukemia Relapsed Acute Lymphoblastic Leukemia (ALL) Relapsed Acute Myelogenous Leukemia (AML) Relapsed Biphenotypic Leukemia Relapsed Mixed Lineage Leukemia
Interventions KPT-330
Updated 24 times since 2017 Last updated: Dec 1, 2025 Started: Mar 31, 2014 Primary completion: Feb 28, 2018 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02091245, this PHASE1 trial focuses on Chronic Myelogenous Leukemia (CML) in Blast Crisis and Refractory Acute Lymphoblastic Leukemia (ALL) and remains ongoing. Sponsored by Dana-Farber Cancer Institute, it has been updated 24 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Mar 2018 · 9 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Feb 2020 · 11 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jan 2022 · 8 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~May 2023 · 5 months · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Jan 2024 · 4 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Aug 2025 · 7 months · monthly snapshot~Aug 2025 – ~Jan 2026 · 5 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

24 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Aug 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 19 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

  3. May 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  7. May 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  8. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1

  9. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  10. Feb 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

  11. Mar 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  12. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  13. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  14. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  15. Jun 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  16. May 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1

  17. Apr 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  18. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Karyopharm Therapeutics Inc
  • William Lawrence and Blanche Hughes Foundation
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations